Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: matched control group Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Ezopiclone Improves the Quality of Overnight Polysomnography

NCT00507117
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Lunesta, Placebo control
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 29, 2007 · Synced Sep 15, 2026, 2:50 AM EDT
Not listed No phase listed Observational

The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support

NCT03472768
View directory record Official record
Conditions
Respiratory Failure
Interventions
Plasma Haptoglobin Concentration
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of BI 1356 in Combination With Metformin in Patients With Type 2 Diabetes

NCT00622284
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo identical to BI 1356 5mg, Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, BI 1356, Glimepiride
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
23
States / cities
Tempe, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 15, 2026, 2:50 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment

NCT06247085
View directory record Official record
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug · Other
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 15, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

NCT01752985
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
BMS-813160, Placebo matching with BMS-813160
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

NCT02978326
View directory record Official record
Conditions
Postpartum Depression
Interventions
SAGE-217 15/20 mg Oral Solution, Placebo, SAGE 217 30 mg Capsules
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
27
States / cities
Little Rock, Arkansas • Beverly Hills, California • Oceanside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease

NCT01176240
View directory record Official record
Conditions
Orthostatic Hypotension, Parkinson's Disease
Interventions
Droxidopa, Placebo
Drug · Other
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
60
States / cities
Alabaster, Alabama • Gilbert, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Not applicable Interventional

Artificial Intelligence/Machine Learning Modeling on Time to Palliative Care Review in an Inpatient Hospital Population

NCT03976297
View directory record Official record
Conditions
Palliative Care
Interventions
Control Tower
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

NCT04541186
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
Pegozafermin, Placebo
Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
32
States / cities
La Mesa, California • San Francisco, California • Clearwater, Florida + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers

NCT03301870
View directory record Official record
Conditions
Irritation Potential of Topic Agent
Interventions
ATx201 Gel 2%, ATx201 Gel 4%, Positive Control, Negative Control, ATx201 Placebo
Drug
Lead sponsor
UNION therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 15, 2026, 2:50 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

NCT04745351
View directory record Official record
Conditions
COVID-19
Interventions
Remdesivir, RDV Placebo, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
41
States / cities
Birmingham, Alabama • Mobile, Alabama • Eureka, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

NCT04392375
View directory record Official record
Conditions
Preeclampsia Severe
Interventions
Nifedipine 30 MG, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress

NCT02498392
View directory record Official record
Conditions
Depressive Disorder, Anxiety
Interventions
JNJ-42165279, Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Costa Mesa, California • Oceanside, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

NCT03559192
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
JNJ-67953964, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Glendale, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)

NCT04198805
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis
Interventions
Vitamin E [(all-rac)-α-tocopheryl acetate], Omega-3 fatty acid (DHA EE), Omega-3 fatty acid (DHA EE) & Vitamin E [(all-rac)-α-tocopheryl acetate], Placebo
Dietary Supplement · Combination Product · Other
Lead sponsor
Naga P. Chalasani
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Gender-Responsive Drug Use Treatment for Juvenile Justice Girls

NCT02293057
View directory record Official record
Conditions
Drug Use
Interventions
VOICES Group, Girl Health Group
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
12 Years to 24 Years · Female only
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 15, 2026, 2:50 AM EDT
Withdrawn Phase 2 Interventional

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

NCT04209556
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
PF-06826647 100 mg QD, PF-06826647 300 mg QD, PF-06826647 600 mg QD, Placebo, PF-6826647 400 mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
Canoga Park, California • Inglewood, California • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Impact of Bosutinib on Safety, Tolerability, Biomarkers and Clinical Outcomes in Dementia With Lewy Bodies

NCT03888222
View directory record Official record
Conditions
Dementia With Lewy Bodies
Interventions
Placebo Oral Tablet, Bosutinib Oral Tablet
Drug
Lead sponsor
Georgetown University
Other
Eligibility
25 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 15, 2026, 2:50 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Dual-task Training in Older Adults

NCT05296551
View directory record Official record
Conditions
Healthy Aging
Interventions
Motor Task, Cognitive-motor dual-task
Other
Lead sponsor
George Washington University
Other
Eligibility
60 Years to 95 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Not applicable Interventional Results available

Improving Function After Knee Arthroplasty With Weight-Bearing Biofeedback

NCT01333189
View directory record Official record
Conditions
Arthropathy of Knee Joint
Interventions
Weight-bearing biofeedback exercise, Standard of care exercise
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Sep 15, 2026, 2:50 AM EDT
Terminated Phase 4 Interventional Results available

Acthar Gel for Multiple Sclerosis That Keeps Getting Better and Worse (RRMS)

NCT03126760
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Acthar Gel, Placebo
Drug
Lead sponsor
Mallinckrodt ARD LLC
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
22
States / cities
Palo Alto, California • Fort Collins, Colorado • Bradenton, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Pride Body Project

NCT03451513
View directory record Official record
Conditions
Eating Disorder, Body Image
Interventions
Pride Body Project, Media Advocacy
Behavioral
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 35 Years
Enrollment
453 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 15, 2026, 2:50 AM EDT
Completed Phase 2 Interventional

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01089010
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Sep 15, 2026, 2:50 AM EDT